FibroBiologics, Inc. (FBLG) AI Stock Analysis

• Market Cap: $17.30M
• Dividend Yield: N/A
• Average Volume (3M): 978.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.40
• Revenue Growth: N/A
• EPS Growth: 18.47%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 66,519,720
• 10 Day Avg. Volume: 1,423,641
• 30 Day Avg. Volume: 978,931
• PEG Ratio: 0.14
• Price to Book (P/B): 24.04
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.44
• Enterprise Value/Market Cap: 1.50
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -112.42
• Enterprise Value/Ebitda: -1.46
• 1Y Price Target: $3.25
• Price Target Upside: 855.88% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $0.33 ▼(-2.06% Downside)

The score is primarily constrained by weak financial fundamentals (no revenue, widening losses, higher cash burn) and an increasingly risky capital structure. Technicals are mixed with only modest near-term momentum and a weaker longer-term trend, while valuation provides little support due to negative earnings. Added downside risk comes from the Nasdaq delisting/reverse-split situation.

Positive Factors

IND filing advancing CYPS317 to clinical stage

Filing a Phase 1/2 IND moves CYPS317 from preclinical to regulatory review, structurally de-risking the program by enabling first-in-human data. Clinical entry creates discrete milestones, potential partner interest, and a clearer timeline for capital allocation and value realization.

Preclinical FSdC results show strong functional efficacy

Robust preclinical efficacy for FSdC spheroids—sustained structural recovery and statistically significant outcomes—supports platform translational potential. Durable structural repair signals differentiate the technology and strengthen long-term clinical and commercial optionality across regenerative indications.

Platform focus on fibroblast-based regenerative medicine

A platform approach centered on fibroblast biology creates scalable R&D optionality across multiple indications. Platform consistency can lower marginal development cost per program, enable shared manufacturing/process knowledge, and increase licensing or partnership appeal over the medium term.

Negative Factors

Pre-revenue with accelerating cash burn

Sustained net losses and steep negative operating cash flow mean the company must rely on external financing to fund trials. This structural burn rate raises dilution and execution risk, compresses runway, and forces management to prioritize near-term financing over long-term program breadth.

Highly leveraged balance sheet and thin equity cushion

A materially higher debt-to-equity ratio and minimal equity provide limited balance sheet flexibility. This elevates refinancing and covenant risk, constrains capacity to sustain costly clinical programs internally, and increases the likelihood of dilutive financings or distressed transactions over the medium term.

Nasdaq delisting risk and reverse-split uncertainty

Active delisting proceedings create structural liquidity and credibility issues that can impair financing, partnerships, and investor base. Reliance on a reverse split to regain compliance is uncertain and, if unsuccessful, could materially reduce access to capital and hinder long-term program execution.

FibroBiologics, Inc. Business Overview & Revenue Model

Company Description

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

How the Company Makes Money

FibroBiologics, Inc. generates revenue primarily through the development and commercialization of its fibroblast-based therapies. The company may earn income through licensing agreements, partnerships with pharmaceutical companies, and the sale of its therapeutic products once they receive regulatory approval. Additionally, FibroBiologics might secure funding through research grants, equity investments, and collaborations with academic institutions or healthcare organizations. These partnerships and investments support the company's research and development efforts, facilitating the advancement of its innovative therapies to the market.

FibroBiologics, Inc. Financial Statement Overview

Summary

FibroBiologics, Inc. is in a typical pre-revenue biotechnology phase, focusing on R&D with no revenue generation. The financials reveal ongoing losses and dependency on external financing. Despite improvements in equity, the balance sheet shows significant leverage. The company needs to transition towards revenue generation to improve its financial health and achieve sustainability.

Income Statement

FibroBiologics, Inc. has reported no revenue for the past five years, reflecting its pre-revenue stage typical for many biotech firms. The consistent negative EBIT and net income highlight ongoing operational challenges and high R&D expenses. The lack of revenue growth and positive margins demonstrates the company's struggle to achieve profitability.

Balance Sheet

The company's balance sheet reflects high leverage with a debt-to-equity ratio of 0.51. However, there has been a positive trend in equity from negative to positive territory over the years. Despite this, the equity ratio is low at 16.63%, indicating a reliance on liabilities. The improvement in cash and short-term investments suggests better liquidity management.

Cash Flow

FibroBiologics, Inc. continues to report negative operating and free cash flows, reflecting its investment-heavy model with no revenue generation. The fluctuating and negative free cash flow growth rates highlight cash management challenges. The company relies heavily on financing activities to sustain operations, which could pose risks if external funding becomes constrained.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-231.00K	0.00	0.00	0.00	0.00	0.00
EBITDA	-17.74M	-10.57M	-15.90M	-4.37M	-1.58M	0.00
Net Income	-18.50M	-11.16M	-16.48M	-5.12M	-1.58M	-1.17M
Balance Sheet
Total Assets	8.74M	16.45M	11.82M	4.82M	468.00K	0.00
Cash, Cash Equivalents and Short-Term Investments	4.87M	13.98M	9.16M	2.27M	407.00K	0.00
Total Debt	7.11M	10.55M	1.75M	7.52M	1.30M	0.00
Total Liabilities	8.62M	13.71M	10.57M	8.82M	1.76M	0.00
Stockholders Equity	125.00K	2.73M	1.25M	-4.00M	-1.29M	0.00
Cash Flow
Free Cash Flow	-16.66M	-12.09M	-6.90M	-4.07M	-1.41M	-1.17M
Operating Cash Flow	-16.30M	-11.90M	-6.40M	-4.07M	-1.41M	-1.17M
Investing Cash Flow	-361.00K	-184.00K	-495.00K	0.00	0.00	0.00
Financing Cash Flow	13.71M	16.91M	13.79M	5.92M	1.82M	1.17M

FibroBiologics, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.34
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBLG, the sentiment is Positive. The current price of 0.34 is above the 20-day moving average (MA) of 0.27, above the 50-day MA of 0.31, and below the 200-day MA of 0.62, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 60.96 is Neutral, neither overbought nor oversold. The STOCH value of 66.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FBLG.

FibroBiologics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLRX	48 Neutral	$13.18M	-2.13	-22.03%	―	-41.76%	87.36%
CRIS	45 Neutral	$12.93M	-0.23	―	―	13.56%	52.92%
FBLG	44 Neutral	$17.30M	-0.71	-1292.87%	―	―	18.47%
SYBX	43 Neutral	$13.92M	-4.45	-27.54%	―	-100.00%	93.62%
PCSA	41 Neutral	$7.66M	-0.10	-270.74%	―	―	72.88%

FibroBiologics, Inc. Corporate Events

FibroBiologics Faces Nasdaq Delisting, Plans Reverse Split

On July 1, 2025, FibroBiologics, Inc. was notified by Nasdaq that its common stock had traded below the $1.00 minimum bid price for 30 consecutive trading days, triggering a 180-day grace period, through December 29, 2025, to regain compliance. After the company failed to meet the requirement by that deadline, Nasdaq staff notified FibroBiologics on December 30, 2025, of its intention to delist the stock unless the company requested a hearing, which FibroBiologics plans to do, temporarily staying any suspension or delisting. The company is monitoring its share price and, as part of its efforts to regain compliance, filed definitive proxy materials on December 29, 2025 seeking shareholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-30, though there is no assurance it will secure an extension or that these measures will succeed, leaving its Nasdaq listing status uncertain for investors.

The most recent analyst rating on (FBLG) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.

FibroBiologics Enters Securities Purchase Agreement

On December 14, 2025, FibroBiologics, Inc. entered into a securities purchase agreement with institutional investors to issue and sell 5,227,275 shares of common stock at $0.33 per share in a registered direct offering, alongside issuing warrants for the same number of shares in a concurrent private placement. The gross proceeds from these offerings are expected to be approximately $1.7 million, with potential additional proceeds if warrants are exercised. The company plans to use the net proceeds for working capital and general corporate purposes, and the offerings are expected to close around December 16, 2025, subject to customary conditions.

The most recent analyst rating on (FBLG) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.

FibroBiologics Announces Securities Purchase Agreement

On November 24, 2025, FibroBiologics, Inc. announced it entered into a securities purchase agreement with institutional investors for a registered direct offering of 4,477,614 shares of common stock at $0.335 per share, expected to raise approximately $1.5 million. Additionally, in a concurrent private placement, the company will issue warrants for the same number of shares, subject to stockholder approval. The proceeds will be used for working capital and general corporate purposes, with H.C. Wainwright & Co. acting as the exclusive placement agent. The offering is expected to close on or about November 25, 2025, pending customary closing conditions.

The most recent analyst rating on (FBLG) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.

FibroBiologics Enters Securities Purchase Agreement with Investor

On November 18, 2025, FibroBiologics, Inc. entered into a securities purchase agreement with an investor to issue and sell 3,540,000 shares of common stock and pre-funded warrants for 8,570,203 shares in a registered direct offering. The purchase price is paid in sovereign-issued gold coins, which the company plans to convert into U.S. dollars. The gross proceeds are expected to be approximately $4 million, with additional potential proceeds from unregistered warrants contingent on stockholder approval. The offering aims to strengthen FibroBiologics’ capital structure and support general corporate purposes, including debt satisfaction. However, the use of gold coins introduces valuation and operational risks due to market volatility and logistical challenges, which could impact the company’s financial performance.

The most recent analyst rating on (FBLG) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.